Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.66 |
| ▸ | PSEN1 | P49768 | 16/20 | 0.61 |
| ▸ | PSEN2 | P49810 | 16/20 | 0.61 |
| ▸ | APH1B | Q8WW43 | 16/20 | 0.61 |
| ▸ | NCSTN | Q92542 | 16/20 | 0.61 |
| ▸ | APH1A | Q96BI3 | 16/20 | 0.61 |
| ▸ | PSENEN | Q9NZ42 | 16/20 | 0.61 |
| ▸ | CCKBR | P32239 | 2/20 | 0.51 |
| ▸ | CCKAR | P32238 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3595087 | 0.92 | KCNH2 (0.78) | KCNH2PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL13865657 | 0.92 | KCNH2 (0.78) | KCNH2PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL3588136 | 0.92 | PSEN1 (0.70) | KCNH2PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL5370070 | 0.92 | PSEN1 (0.70) | KCNH2PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL13502683 | 0.91 | KCNH2 (0.72) | KCNH2PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL3587719 | 0.89 | PSEN1 (0.67) | KCNH2PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL13675304 | 0.89 | PSEN1 (0.58) | KCNH2PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL13675241 | 0.89 | PSEN1 (0.53) | KCNH2PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL13675155 | 0.87 | CCKBR (0.64) | KCNH2PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL3588536 | 0.86 | PSEN1 (0.63) | KCNH2PSEN1PSEN2APH1BNCSTN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090264419-A1 | CYCLIC MALONAMIDES AS INHIBITORS OF Abeta PROTEIN PRODUCTION | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2009-10-22 | — | — | US | disclosed |
| US-7390896-B2 | Cyclic malonamides as inhibitors of Aβ protein production | BRISTOL-MYERS SQUIBB PHARMA CORPORATION (US) | 2008-06-24 | — | — | US | disclosed |
| US-20080021014-A1 | CYCLIC MALONAMIDES AS INHIBITORS OF Abeta PROTEIN PRODUCTION | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2008-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264419-A1 | CYCLIC MALONAMIDES AS INHIBITORS OF Abeta PROTEIN PRODUCTION | APP, BACE1, APBA1 | KCNH2 2256/4885PSEN1 6/4885PSEN2 9/4885 |
| US-20080021014-A1 | CYCLIC MALONAMIDES AS INHIBITORS OF Abeta PROTEIN PRODUCTION | APP, BACE1, APBA1 | KCNH2 2256/4885PSEN1 6/4885PSEN2 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.